Patents by Inventor Arthur Levin

Arthur Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BACKBONE MODIFICATIONS TO MODULATE OLIGONUCLEOTIDE TARGETING IN VIVO
    Publication number: 20070299028
    Abstract: The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes PTEN, SGLT2 and connective tissue growth factor (CTGF) in the kidney.
    Type: Application
    Filed: February 26, 2007
    Publication date: December 27, 2007
    Inventors: Andrew Siwkowski, Edward Wancewicz, Thomas Leedom, Lynnetta Watts, Mausumee Guha, Brett Monia, Richard Griffey, Richard Geary, Scott Henry, Arthur Levin
  • Liposomal oligonucleotide compositions for modulating RAS gene expression
    Patent number: 6083923
    Abstract: Pharmaceutical compositions comprising sterically stabilized liposomes containing antisense oligonucleotides are provided for the modulation of expression of the human ras gene in both the normal (wildtype) and activated (mutant) forms.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: July 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Gregory E. Hardee, Richard S. Geary, Arthur Levin, Michael V. Templin, Randy Howard, Rahul C. Mehta
  • Prevention and treatment of premalignant epithelial lesions and malignant tumors of epithelial origin
    Patent number: 5428071
    Abstract: The compound 9-cis-retinoic acid, its pharmaceutically acceptable salts or its pharmaceutically acceptable esters can be used in the treatment of precancerous or premalignant epithelial lesions as well as in the treatment of malignant tumors of an epithelial nature.
    Type: Grant
    Filed: February 24, 1994
    Date of Patent: June 27, 1995
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Werner Bollag, Joseph F. Grippo, Arthur Levin